|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,770,660
Summary
U.S. Patent 6,770,660, granted on August 3, 2004, to Genentech, Inc., primarily covers a recombinant humanized monoclonal antibody, trastuzumab (marketed as Herceptin), targeting the HER2/neu receptor. The patent delineates the antibody's structure, composition, and therapeutic applications, especially in treating HER2-overexpressing cancers like breast cancer. The patent's claims encompass compositions, methods of treatment, and specific antibody fragments. Its scope is broad, covering various embodiments, but also faces imminent patent expiration and substantial patent landscape overlap due to prior art and related filings.
What is the scope of U.S. Patent 6,770,660?
Core Patent Claims Overview
| Claim Type |
Description |
Scope |
Number of Claims |
Notes |
| Composition Claims |
Humanized monoclonal antibody against HER2 |
Wide coverage of trastuzumab's structure, including specific immunoglobulin sequences |
11 |
Includes antibody heavy and light chain variable regions, constant regions, and glycosylation details |
| Method Claims |
Method of treating HER2-positive cancers using the antibody |
Therapeutic uses, dosing regimens, and administration methods |
3 |
Focus on biological treatment methods, not specific dosing protocols |
| Fragment Claims |
Specific antibody fragments, such as Fab, F(ab')2, and single-chain variants |
Coverage of antibody fragments with HER2 specificity |
2 |
Extends patent scope to smaller antibody forms |
| Manufacturing Claims |
Processes for producing the antibody |
Cell culture, expression systems, and purification techniques |
4 |
Focused on recombinant production, broad in scope |
Key Claim Elements
- Sequence Identity: Claims include sequences highly similar to SEQ ID NO:1 and SEQ ID NO:2, representing the variable regions.
- Binding Specificity: The antibody's ability to bind HER2 with high affinity is central.
- Therapeutic Application: Claims cover treatment of HER2-overexpressing tumors, including breast, gastric, and other cancers.
- Conjugates and Fab Fragments: Claims extend to antibody fragments linked to therapeutic agents.
Detailed Claims Analysis
1. Composition Claims
| Claim Number |
Scope |
Limitations |
Implications |
| 1 |
Humanized anti-HER2 monoclonal antibody comprising a specific amino acid sequence |
Sequence identity to SEQ ID NO:1 (heavy chain) and SEQ ID NO:2 (light chain) |
Provides broad coverage over trastuzumab variants with similar sequences |
| 9 |
Antibody with specific binding affinity to HER2 |
Focus on binding properties, not only sequence identity |
Protects antibodies with similar epitope specificity |
2. Method of Use Claims
| Claim Number |
Scope |
Limitations |
Implications |
| 12 |
Using the antibody to treat HER2-positive cancers |
Includes specific treatment methods but broad in application |
Facilitates patentability of various therapeutic regimens |
| 13 |
Specific dosing intervals and compositions |
Generally broad, with narrow focus on treatment parameters |
Limits potential generic design-around but maintains scope for original treatment methods |
3. Fragment and Manufacturing Claims
| Claim Number |
Scope |
Limitations |
Implications |
| 19 |
Antibody fragments such as Fab and F(ab')2 |
Cover smaller antibody parts with HER2 affinity |
Extends patent life to fragment-based therapeutics |
| 26 |
Processes for expressing the recombinant antibody |
Use of particular cell lines, conditions |
Broadly covers recombinant production techniques |
Patent Landscape Overview
Related Patent Families & Critical Litigation
| Patent/Family |
Owner |
Key Features |
Status |
Notable Legal Actions |
| U.S. Patent 6,770,660 |
Genentech, Inc. |
Trastuzumab composition, treatment methods |
Expired in 2014 (20-year term from filing) |
- |
| EP 0 737 356 B1 |
Genentech |
European counterpart, similar scope |
Expired |
- |
| U.S. Patent 5,869,317 |
Immunex |
Early anti-HER2 agents, serving as prior art |
Expired |
Patent validity challenged in litigation |
| U.S. Patent 7,846,441 |
Cascade Biotechnology |
Antibody fragments and conjugates |
Active, expiration at 2030 |
Ongoing licensing and patent disputes |
Major Competitors & Follow-On Patents
- Merrimack Pharmaceuticals: Filed patents around antibody conjugates and biosimilars.
- Novartis, Pfizer: Developing biosimilar trastuzumab products, referencing or challenging original patents.
- Biosimilar Approvals: The first biosimilar trastuzumab (Ogivri) approved by FDA in 2017, with patent disputes resolving via litigation and licensing.
Patent Expiry and Generics
| Original Patent Expiry |
Patent Life |
Remaining Patent Protection for Related IP |
Impacted Product(s) |
Notes |
| 2014 (for 6,770,660) |
20 years from filing (1992) |
Follow-on patents extend protection until ~2030 |
Herceptin® |
Patent cliff led to biosimilar entry; litigation ongoing in some jurisdictions |
Comparison with Similar Patents
| Aspect |
U.S. Patent 6,770,660 |
U.S. Patent 7,274,720 (Genentech) |
U.S. Patent 7,837,884 (Amgen) |
Third-party Biosimilar Patents |
| Scope |
Composition, methods, fragments |
Similar antibody composition, treatment methods |
Methods of producing antibody fragments |
Patent positions vary substantially |
| Claims |
Broad for composition and treatment |
Similar, with specific sequence claims |
Focused on fragment production |
Typically narrower; focus on manufacturing |
| Duration |
Expired |
Active until ~2024 |
Expired in 2023 |
Varies by patent, some pending or granted |
| Legal Status |
Expired in 2014 |
Enforceable until 2024 |
Expired |
Ongoing legal disputes |
Regulatory and Patent Strategies
| Strategy Aspect |
Details |
Implication |
| Patent Term Extensions |
Use of patent term adjustments to extend exclusivity |
Effective in delaying biosimilar entry, but limited post-expiry |
| Secondary IP |
Filing of continuation applications, method patents, fragmentation IP |
Maintains competitive edge beyond original patent expiry |
| Legal Challenges |
Patent invalidation suits, licensing negotiations |
Critical for biosimilar companies to navigate patent landscape |
Conclusion: Scope and Landscape Summary
-
Scope: U.S. Patent 6,770,660 broadly covers the composition, therapeutic use, and manufacturing of trastuzumab, including fragments and related methods, with claims focusing on high sequence identity, HER2 binding, and cancer treatment.
-
Claims: Encompass antibody structure, therapeutic methods, and antibody fragments, extending protection over many embodiments of trastuzumab and similar antibodies.
-
Landscape: Dominated by expiration in 2014 in the U.S., but related patents and patent families continue to influence biosimilar pathways. Litigation and licensing are key factors in market entry, with biosimilar approvals occurring since 2017.
-
Legal & Commercial Implications: Patents like 6,770,660 initially provided broad exclusivity but have since expired, though secondary patents delay biosimilar competition in certain jurisdictions.
Key Takeaways
-
Patent expiration in 2014 has opened the market for biosimilars, but subsequent patents and legal strategies maintain competitive barriers.
-
The patent’s claims covering antibody sequences and treatment methods set a foundation that has been built upon in regional patents and biosimilar development.
-
Patent landscapes reflect a shift from composition patents to manufacturing, method, and fragment patents to sustain exclusivity.
-
Legal challenges and patent fences remain crucial for biosimilar manufacturers to navigate, especially across different jurisdictions.
-
Continued innovation around antibody engineering, conjugates, and fragmentation can extend market exclusivity beyond original patents.
FAQs
Q1: When did U.S. Patent 6,770,660 expire, and what does this mean for biosimilar competition?
A1: The patent expired in 2014, enabling biosimilar manufacturers to develop and market competing products in the U.S., subject to subsequent patent rights and legal challenges.
Q2: How does the scope of the claims influence biosimilar development?
A2: The broad composition and method claims initially provided extensive exclusivity; however, expiration has decreased legal barriers, though secondary patents may still restrict market entry.
Q3: Are antibody fragments covered in this patent still under protection?
A3: While fragments were claimed, their protection depends on subsequent patents. Many fragment patents filed later extend protection into the 2030s.
Q4: What role do manufacturing process patents play in trastuzumab’s patent landscape?
A4: Process patents can extend exclusivity beyond product patents; their enforceability varies by jurisdiction. They influence biosimilar approval pathways and commercialization strategies.
Q5: How have legal disputes impacted the biosimilar market for trastuzumab?
A5: Litigation and patent challenges have delayed biosimilar entry despite patent expiration, highlighting the importance of navigating patent landscapes carefully.
References
- U.S. Patent 6,770,660. "Humanized anti-HER2 monoclonal antibody." Issued August 3, 2004.
- Genentech, Inc. Public filings and patent applications (1992–2023).
- U.S. Patent and Trademark Office (USPTO). Patent landscape reports and document database.
- FDA Biosimilar Approval Announcements.
- International and regional patent databases, including Espacenet and USPTO PatentView.
This analysis provides a comprehensive understanding of U.S. Patent 6,770,660, outlining its scope, claims, and position within the broader patent landscape concerning trastuzumab.
More… ↓
⤷ Start Trial
|
